Last reviewed · How we verify
NCT04306094: LUPROG
Factors Determining the Prognosis in NSCLC Stage IV
trial in NSCLC Stage IV in 217 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Instituto do Cancer do Estado de São Paulo |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 217 |
| Start date | 1 November 2017 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 February 2022 |
| Sites | 1 location across Brazil |
Conditions studied
- NSCLC Stage IV — all drugs for NSCLC Stage IV →
Sponsor
Instituto do Cancer do Estado de São Paulo — full company profile →
Who can join
18 and older, any sex, with NSCLC Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a cohort study with patients with advanced NSCLC. Patients will answer questionnaires about symptoms and quality of life and will be submitted to physical and blood tests, and computer tomography. The aim of this study is to estimate prognostic factors predicting survival to 3 months in patients with advanced NSCLC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting survival in metastatic non-small cell lung cancer patients with poor ECOG-PS: A single-arm prospective study.
Cunha MT, de Souza Borges AP, Carvalho Jardim V, Fujita A, et al · · 2023 · cited 3× · PMID 36161783 · DOI 10.1002/cam4.5254
Verify or expand the search:
- PubMed search for NCT04306094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC Stage IV
Currently open trials in the same condition.
- NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
- NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
- NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting
Other Instituto do Cancer do Estado de São Paulo trials
Trials by the same sponsor.
- NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
- NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
- NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
- NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
- NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04306094 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
- Last refreshed: 12 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04306094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing